Study S001369

A Phase 1b, Exploratory, Randomized, Partially Single Blinded, Placebo and Open Label Controlled, Parallel Group Study to Assess the Effects of HM11260C and an Active Comparator on Gastric Emptying and Beta-Cell Response in Subjects With Type 2 Diabetes Mellitus

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT02059564
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: QUADRUPLE
Status: UNKNOWN
Enrollment: 44
Start: 2013-12
Primary completion: 2014-10
Lead sponsor: Hanmi Pharmaceutical Company Limited
Conditions: Diabetes Mellitus
Interventions: DRUG:HM11260C; DRUG:Placebo; DRUG:Victoza
Results posted: FALSE

Registered primary outcomes

PK profile of acetaminophen [13 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0008346	Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study. Hompesch M, BMJ open diabetes research & care	2021	Randomized trial	PMID 34172436 DOI	cites ClinicalTrials.gov:NCT02059564; registry reference DERIVED:34172436